(CRNX) Crinetics Pharmaceuticals - NASDAQ

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.471m USD | Total Return: 3.7% in 12m

Endocrine Therapeutics, Hormone Agonists, Hormone Antagonists
Total Rating 21
Safety 32
Buy Signal -0.98
Biotechnology
Industry Rotation: -7.2
Market Cap: 3.47B
Avg Turnover: 31.3M
Risk 3d forecast
Volatility54.9%
VaR 5th Pctl8.54%
VaR vs Median-6.15%
Reward TTM
Sharpe Ratio0.26
Rel. Str. IBD15.2
Rel. Str. Peer Group14.2
Character TTM
Beta1.142
Beta Downside1.053
Hurst Exponent0.444
Drawdowns 3y
Max DD57.88%
CAGR/Max DD0.30
CAGR/Mean DD0.81
EPS (Earnings per Share) EPS (Earnings per Share) of CRNX over the last years for every Quarter: "2021-06": -0.7, "2021-09": -0.73, "2021-12": -0.68, "2022-03": -0.73, "2022-06": -0.81, "2022-09": -0.78, "2022-12": -0.84, "2023-03": -0.85, "2023-06": -0.94, "2023-09": -1.01, "2023-12": -0.9, "2024-03": -0.93, "2024-06": -0.94, "2024-09": -0.96, "2024-12": -0.88, "2025-03": -1.04, "2025-06": -1.23, "2025-09": -1.38, "2025-12": -1.29, "2026-03": -1.23,
Last SUE: -0.55
Qual. Beats: 0
Revenue Revenue of CRNX over the last years for every Quarter: 2021-06: 0.005602, 2021-09: 0.006227, 2021-12: 1.078, 2022-03: 3.131, 2022-06: 0.439, 2022-09: 0.458, 2022-12: 0.709, 2023-03: 2.679, 2023-06: 0.988, 2023-09: 0.346, 2023-12: 0, 2024-03: 0.64, 2024-06: 0.399, 2024-09: 0, 2024-12: 0, 2025-03: 0.361, 2025-06: 1.031, 2025-09: 0.143, 2025-12: 6.161, 2026-03: 10.734,
Rev. CAGR: 12.82%
Rev. Trend: 11.3%
Last SUE: 3.65
Qual. Beats: 2

Warnings

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Fakeout Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: CRNX Crinetics Pharmaceuticals

Crinetics Pharmaceuticals (CRNX) is a clinical-stage biotechnology firm specializing in oral nonpeptide therapeutics for rare endocrine disorders and endocrine-related tumors. Its primary candidate, Paltusotine, is currently in Phase 3 clinical trials for acromegaly and carcinoid syndrome, aiming to provide an oral alternative to traditional injectable somatostatin analogs. The company’s pipeline extends to treatments for Congenital Adrenal Hyperplasia, Cushing’s disease, and metabolic conditions including obesity via oral GLP-1 and GIP agonists.

The biotechnology sector often utilizes a platform-based discovery model to develop small molecule drugs that target G-protein coupled receptors (GPCRs), a major class of drug targets in endocrinology. Unlike many rare disease competitors that rely on complex biologics, Crinetics focuses on synthetic nonpeptides which generally offer easier administration and simplified manufacturing scales. Strategic partnerships with Sanwa Kagaku Kenkyusho and Cellular Longevity support the companys international and specialized development efforts.

Reviewing the latest institutional ownership data on ValueRay can offer further perspective on the companys market position.

Headlines to Watch Out For
  • Paltusotine NDA submission for acromegaly drives near-term regulatory and commercial valuation
  • Phase 3 carcinoid syndrome data determines expansion into neuroendocrine tumor markets
  • Atumelnant clinical trial results impact long-term pipeline value in adrenal disease
  • R&D expenditure and cash burn rates dictate future equity financing needs
  • Strategic partnerships in Japan and obesity space influence non-dilutive capital inflows
Piotroski VR-10 (Strict) 0.0
Net Income: -496.4m TTM > 0 and > 6% of Revenue
FCF/TA: -0.30 > 0.02 and ΔFCF/TA -10.45 > 1.0
NWC/Revenue: 6.93k% < 20% (prev 162k%; Δ -155k% < -1%)
CFO/TA -0.30 > 3% & CFO -414.2m > Net Income -496.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 18.60 > 1.5 & < 3
Outstanding Shares: last quarter (104.1m) vs 12m ago 11.81% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 1.31% > 50% (prev 0.06%; Δ 1.25% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 10.00
A: 0.89 (Total Current Assets 1.32b - Total Current Liabilities 71.1m) / Total Assets 1.40b
B: -1.10 (Retained Earnings -1.55b / Total Assets 1.40b)
C: -0.40 (EBIT TTM -545.7m / Avg Total Assets 1.38b)
D: 10.61 (Book Value of Equity 1.28b / Total Liabilities 120.7m)
Altman-Z'' = 10.75 = AAA
Beneish M 1.00
DSRI: 0.10 (Receivables 5.68m/7.31m, Revenue 18.1m/760k)
GMI: 1.00 (fallback, negative margins)
AQI: 1.66 (AQ_t 0.02 / AQ_t-1 0.01)
SGI: 23.77 (Revenue 18.1m / 760k)
TATA: -0.06 (NI -496.4m - CFO -414.2m) / TA 1.40b)
Beneish M = 12.95 (Cap -4..+1) = D
What is the price of CRNX shares?

As of June 12, 2026, the stock is trading at USD 33.53 with a total of 1,728,773 shares traded.
Over the past week, the price has changed by -3.18%, over one month by -8.26%, over three months by -9.33% and over the past year by +3.71%.

Is CRNX a buy, sell or hold?

Crinetics Pharmaceuticals has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy CRNX.

  • StrongBuy: 11
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CRNX price?
Analysts Target Price 83.1 148%
Crinetics Pharmaceuticals (CRNX) - Fundamental Data Overview as of 09 June 2026
Market Cap USD = 3.47b (3.47b USD * 1.0 USD.USD)
P/S = 192.102
P/B = 2.8512
Revenue TTM = 18.1m USD
EBIT TTM = -545.7m USD
EBITDA TTM = -541.6m USD
Long Term Debt = 41.3m USD (estimated: total debt 47.9m - short term 6.54m)
Short Term Debt = 6.54m USD (from shortTermDebt, last quarter)
Debt = 47.9m USD (from shortLongTermDebtTotal, last quarter) (leases 47.9m already included)
Net Debt = -1.24b USD (calculated: Debt 47.9m - CCE 1.29b)
Enterprise Value = 2.23b USD (3.47b + Debt 47.9m - CCE 1.29b)
 Interest Coverage Ratio = unknown (Ebit TTM -545.7m / Interest Expense TTM 0.0)
 EV/FCF = -5.31x (Enterprise Value 2.23b / FCF TTM -419.5m)
FCF Yield = -18.83% (FCF TTM -419.5m / Enterprise Value 2.23b)
 FCF Margin = -2.32k% (FCF TTM -419.5m / Revenue TTM 18.1m)
 Net Margin = -2.75k% (Net Income TTM -496.4m / Revenue TTM 18.1m)
 Gross Margin = unknown ((Revenue TTM 18.1m - Cost of Revenue TTM 91.2m) / Revenue TTM)
 Tobins Q-Ratio = 1.59 (Enterprise Value 2.23b / Total Assets 1.40b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 47.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -431.1m (EBIT -545.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.60 (Total Current Assets 1.32b / Total Current Liabilities 71.1m)
Debt / Equity = 0.04 (Debt 47.9m / totalStockholderEquity, last quarter 1.28b)
 Debt / EBITDA = 2.30 (negative EBITDA) (Net Debt -1.24b / EBITDA -541.6m)
 Debt / FCF = 2.96 (negative FCF - burning cash) (Net Debt -1.24b / FCF TTM -419.5m)
 Total Stockholder Equity = 1.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -35.94% (Net Income -496.4m / Total Assets 1.40b)
RoE = -43.96% (Net Income TTM -496.4m / Total Stockholder Equity 1.13b)
RoCE = -46.63% (EBIT -545.7m / Capital Employed (Equity 1.13b + L.T.Debt 41.3m))
 RoIC = -32.27% (negative operating profit) (NOPAT -431.1m / Invested Capital 1.34b)
 WACC = 9.86% (E(3.47b)/V(3.52b) * Re(10.0%) + D(47.9m)/V(3.52b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 21.52%
 [DCF] Fair Price = unknown (Cash Flow -419.5m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.55 | # QB: 0
Revenue Correlation: 11.30 | Revenue CAGR: 12.82% | SUE: 3.65 | # QB: 2
EPS current Quarter (2026-06-30): EPS=-1.23 | Chg30d=-0.65% | Revisions=-8% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-1.22 | Chg30d=+0.89% | Revisions=+23% | Analysts=10
EPS current Year (2026-12-31): EPS=-4.78 | Chg30d=-0.02% | Revisions=+8% | GrowthEPS=+3.4% | GrowthRev=+790.7%
EPS next Year (2027-12-31): EPS=-4.21 | Chg30d=-3.19% | Revisions=-17% | GrowthEPS=+12.0% | GrowthRev=+152.4%
[Analyst] Revisions Ratio: +23%